Interestingly, in two neuroblastoma patient cohorts, the presence of TAMs expressing PD-L1, as well as the expression of the SLAMF7 pathway and CD163 in TAMs, was found to be beneficial for high-risk patients and correlated with improved survival following immunotherapy [77]. Here, CD163 is linked to neuroblastoma.